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Abstract
Glycoprotein receptors are influenced by myriad intermolecular interactions at the cell
surface. Specific glycan structures may interact with endogenous lectins that enforce or dis-
rupt receptor-receptor interactions. Glycoproteins bound by multivalent lectins may form
extended oligomers or lattices, altering the lateral mobility of the receptor and influencing its
function through endocytosis or changes in activation. In this study, we have examined the
interaction of Galectin-3 (Gal-3), a human lectin, with adhesion receptors. We measured the
effect of recombinant Gal-3 added exogenously on the lateral mobility of the α5β1 integrin
on HeLa cells. Using single-particle tracking (SPT) we detected increased lateral mobility of
the integrin in the presence of Gal-3, while its truncated C-terminal domain (Gal-3C) showed
only minor reductions in lateral mobility. Treatment of cells with Gal-3 increased β1-integrin
mediated migration with no apparent changes in viability. In contrast, Gal-3C decreased
both cell migration and viability. Fluorescence microscopy allowed us to confirm that exoge-
nous Gal-3 resulted in reorganization of the integrin into larger clusters. We used a proteo-
mics analysis to confirm that cells expressed endogenous Gal-3, and found that addition of
competitive oligosaccharide ligands for the lectin altered the lateral mobility of the integrin.
Together, our results are consistent with a Gal-3–integrin lattice model of binding and con-
firm that the lateral mobility of integrins is natively regulated, in part, by galectins.
Introduction
Galectins are a family of animal lectins well known to oligomerize glycoprotein receptors, a
feature typically ascribed to their multivalent structure.[1],[2] There are 15 known human
galectins, which are classified into three structural families.[3] Galectins are either multivalent
or able to oligomerize, and their ligands on the cell surface often contain multiple binding
sites. Thus, one of the key functions of galectins is their modulation of cell surface receptor
organization. Galectin-ligand interactions are generally thought to form oligomer or lattice
structures which may regulate the function of receptors on the cell surface.[4–7] The typical
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ligand motif for galectins includes a terminal β-galactoside, a binding epitope that can be
masked by sialylation of glycans.[8],[9] Galectins are known to regulate a number of pathways
including apoptosis,[10] immune tolerance, inflammation,[11] and cell adhesion.[12]
In the case of Galectin-3 (Gal-3; also referred to as Mac-2 or LGALS3),[13] the protein is
not a covalent dimer. Oligomerization of Gal-3 is largely mediated by the N-terminal domain,
which may involve binding of phospho–Ser and–Thr sites.[14] However, the truncated C-ter-
minal domain can also oligomerize in the presence of ligand,[15] and on the cell surface.[16]
The crosslinking of receptors by Gal-3 can result in attenuation and activation of signaling
pathways,[17] as well as processes including proliferation,[18] phagocytosis,[19] endocytosis,
[20, 21] and atherosclerosis.[22] Importantly, Gal-3 has been implicated in the regulation of
cell adhesion.[23] Gal-3 enhances leukocyte adhesion,[24],[25] and metastasis in cancer cells.
[26–29]
Galectin-3 may mediate cellular pathways by crosslinking of receptors in cis, or through
bridging of receptors to extracellular targets in trans. The affinity of Gal-3 for oligosaccharides
has been studied by calorimetry and mass spectrometry, and its highest affinity ligands tend to
be N-acetyl-lactosamine (LacNAc) or lacto-N-neotetraose (LNnT) analogs.[30],[31] Specific
glycoprotein targets of Gal-3 include extracellular matrix proteins, such as laminin and fibro-
nectin (FN).[32] Gal-3 can stabilize focal adhesions,[33] and regulate remodeling of extracellu-
lar matrix.[34] Gal-3 itself has been reported to be a substrate of matrix metalloproteases,
which may regulate its function.[35] Adhesion receptors bound by Gal-3 include integrins and
immune receptors.[21, 36–39] The oligomerization of integrin receptors by Gal-3 has been
observed for a variety of receptors on multiple cell types. Gal-3–mediated clustering has been
associated with β1 integrin endocytosis,[40] complex formation of the α3β1 integrin,[41]
adhesion of α2β1 integrin to collagen,[42] and regulation of the dynamics of α5β1 integrin
complexes.[33] Interaction of Gal-3 with integrins involves terminal galactose residues, and is
blocked by the presence of sialic acid residues.[8],[43]
Our group has been interested in the regulatory function of neuraminidase enzymes (NEU;
also called sialidases) in adhesion. The activity of NEU may enhance the function of galectins
by revealing cryptic binding sites for receptor crosslinking.[44] While there are a number of
studies that have used fluorescence microscopy to determine gross changes to galectin-induced
receptor oligomerization, few have quantified these effects on galectin ligands on cells. Belardi
et al. reported experiments with artificial Galectin-1 (Gal-1) ligands on cells, where they
observed reduced lateral mobility and cluster formation.[45] Galectin-1 has been reported to
reduce the lateral mobility of the NiV-F viral fusion protein.[46] The binding of Gal-1 to
H-Ras has been detected using FLIM-FRET methods.[47] These examples examined effects of
Gal-1, a homodimeric galectin. The effects of a monomeric galectin, such as Gal-3, have not
been examined in the same detail.[48] In general, the ability of Gal-3 to oligomerize receptors
on the cell has been assessed using fluorescence microscopy. Examples of Gal-3 receptor clus-
tering as determined by microscopy include mucins,[49],[50] CD71,[39] CD147,[51] the α3β1
integrin,[52] and the αvβ3 integrin.[53] Galectin-3 binds targets in vitro through positive
cooperativity,[54] and studies of Gal-3 binding to cellular receptors with FRET has confirmed
lattice formation.[16]
We considered that there was a need for the use of quantitative measurements of Gal-3–
mediated receptor crosslinking, which could be used to investigate the effect of Gal-3 on adhe-
sion receptors. Aggregated receptors within the membrane will have a larger cross-section
than individual receptors, and could therefore show reduced lateral mobility.[55] Receptor
crosslinking may also result in binding of intracellular or extracellular components which can
influence diffusivity,[17, 56] and in turn regulate intracellular signaling. In previous studies of
NEU on integrin–mediated adhesion we found that α5β1 integrin was positively regulated by
Galectin-3 effects on beta-1-integrin mobility
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human NEU.[44] Herein, we investigate the ability of Gal-3 to interact with the α5β1 integrin.
We used measurement of integrin lateral mobility by single particle tracking (SPT) as our pri-
mary tool.[57] Our results confirmed that Gal-3 altered the lateral mobility of the α5β1 integ-
rin. We confirm that changes in lateral mobility manifested as changes to integrin clustering
using fluorescence microscopy. Furthermore, we used exogenous high-affinity oligosaccha-
rides to disrupt Gal-3–integrin interactions, which also led to increased integrin lateral
mobility.
Results
HeLa cells express Gal-1 and Gal-3
We first confirmed that the cell line used for our experiments had native expression of galec-
tins. We selected HeLa cells as they are an adherent line that are known to express Gal-3 and
Gal-1.[58] Cells were grown to confluence, harvested, and lysed. The lysate was passed over an
LNnT or Lac affinity column prepared using DVS chemistry.[59] Analysis of the eluent by
shotgun proteomics methods confirmed the presence of Gal-1 and Gal-3 in HeLa lysate
(Table A in S1 File). We then sought to explore the role of these natively expressed galectins
in regulation of integrin lateral mobility using this cell line.
Lateral mobility of integrin receptors was altered by galectin ligands
To examine the role of endogenous galectins in regulating integrin mobility, we tested whether
a high-affinity oligosaccharide for Gal-3 influenced integrin mobility. Using single-particle
tracking, we measured the lateral mobility of the α5β1 integrin on HeLa cells. Due to the distri-
bution of diffusion coefficients over multiple decades, we interpreted the data as a log-normal
distribution, and compared conditions based on their logarithmic means (Table 1). The affin-
ity of lactose (Lac) and lacto-N-neotetraose (LNnT) for Gal-3 are reported to be 26 and 2 μM,
respectively.[60] The LNnT tetrasaccharide has relatively high affinity for Gal-3C (10.8 μM
Kd),[61] and has low-micromolar affinity to Gal-8 and Gal-9. Integrin mobility was unaffected
by Lac treatment, confirming that the osmotic differences between Lac and buffer did not have
any detectable changes on lateral mobility (see Table C in S1 File). We found that integrin
Table 1. Lateral mobility of integrins.
Condition N mean‡ log mean‡
Control (PBS) 618 1.4 ± 0.2 0.4 ± 0.02
LNnT 177 2.5 ± 0.4*** 0.6 ± 0.05*
Gal-3C 50 μg mL-1 136 1.0 ± 0.2 0.3 ± 0.03
Gal-3 25 μg mL-1 485 1.0 ± 0.1 0.3 ± 0.01*
Gal-3 50 μg mL-1 183 1.8 ± 0.2 0.7 ± 0.05****
NanI 523 1.0 ± 0.1 0.4 ± 0.02
‡, Units are [x 10−10 cm2 sec-1] or [x 10−2 μm2sec-1].
Cells were treated for 0.5 hrs under each condition. p values were calculated by comparison of two normal populations of raw or log-transformed data as
indicated. Samples were compared to the indicated control for significance using a student’s t-test.
*, p 0.05
***, p 0.005
****, p 0.0001.
https://doi.org/10.1371/journal.pone.0184378.t001
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lateral mobility was positively affected by the addition of LNnT, with a significant increase in
mobility (1.3 ± 0.1 x 10−10 cm2 sec-1). This observation may be consistent with the disruption
of galectin-integrin interactions on the cell surface; however, the role of alternative targets for
LNnT cannot be ruled out.
The recognition epitope of many galectins can be masked by sialylation. We considered that
removal of Sia by neuraminidase treatment could reveal cryptic galectin binding sites, which
might then alter integrin-galectin interactions.[8, 62] Cells were treated with a bacterial neur-
aminidase (NanI) that we previously found can de-sialylate the β1 integrin on HeLa.[44] Mea-
surement of integrin lateral mobility showed no significant change to the median mobility after
NanI treatment. However, there is a notable loss of trajectories at higher mobility (>2 x10-10
cm2sec-1) observed in the profile of diffusion coefficients (see Figure B in S1 File). We observed
that the β1 chain of the integrin showed a decrease in molecular weight after NanI treatment, sup-
porting a role for changes in the integrin glycan in regulating its mobility (see Figure C in S1 File).
Lateral mobility of integrin receptors was increased by exogenous
galectin-3
Although our results above suggested the involvement of galectins in regulating integrin
mobility, other lectin-integrin interactions could be responsible for our observations. To pro-
vide more direct evidence of integrin-galectin interactions, we generated recombinant Gal-3
and Gal-3 C-terminal domain (containing only the C-terminal CRD; Gal-3C).[15, 63] The
purified proteins were added to HeLa cell culture, and the lateral mobility of the integrin was
measured (Table 1, Fig 1). The addition of Gal-3C at 50 μg mL-1 gave a small, but insignificant,
reduction in mean lateral mobility of the integrin. The reduction in lateral mobility may be the
result of competition for integrin binding sites which do not lead to clustering. There is a nota-
ble decrease in the number of trajectories found at higher mobility (>2 x10-10 cm2sec-1) in the
Gal-3C profile as compared to the control condition (see Figure B in S1 File). Treatment of
cells with Gal-3 showed an opposite effect to that of Gal-3C; with a significant increase in the
mean lateral mobility of the integrin when used at 50 μg mL-1. The effect of Gal-3 was concen-
tration dependent, as lower concentrations of the Gal-3 protein showed no significant effects
(25 μg mL-1). The active concentration of Gal-3 is known to vary in different cell types and
likely depends on the number of glycan binding sites present and native expression of galectin.
[33] These data suggest that a competent Gal-3 protein has opposite effects on lateral mobility
relative to the CRD of the lectin alone. In general, trajectories observed for integrins were con-
fined, with very few giving the appearance of free diffusion (c.a. < 10%) as determined by a
moment scaling spectrum analysis (MSS).[64]
Exogenous galectin-3 increased the cluster size of integrins
Although we could observe clear changes in integrin lateral mobility, we also wanted to con-
firm that these changes altered distribution of the receptor on the cell surface. The distribution
of integrin receptors was assessed by acquiring TIRF images of antibody-labelled integrin
under each treatment. Images were analyzed for clusters by identifying the pixel area found in
clusters on individual cells by thresholding. Treatment of cells with Gal-3C alone did not show
a significant increase in integrin cluster size, while treatment with both cytochalasin D (cytoD;
a cytoskeletal disruptor) and Gal-3C together increased clustering (Fig 2).[65] Cells treated
with potential ligands of native galectins, Lac, or LNnT oligosaccharides, did not show any
detectable changes in cluster size. Treatment with Gal-3 showed an increase in integrin cluster-
ing. Treatment of cells with cytoD alone also resulted in an increase to clustering of the integ-
rin. The effect of Gal-3 and cytoD were not additive, as the combined treatment (Gal-3
Galectin-3 effects on beta-1-integrin mobility
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+ cytoD) gave a similar increase in clustering to each condition alone. We note that as cytoD
treatment alone had a similar increase in clustering, the combined treatment does support a
substantial effect of Gal-3C on clustering.
Exogenous galectin-3 increased integrin-mediated cell migration
To test the functional effect of changes to integrin lateral mobility and cluster size, we exam-
ined cell migration in the presence of exogenous galectins (Gal-3 and Gal-3C) and galectin
ligands (LNnT). Conditions for migration experiments used the same concentration as those
for lateral mobility experiments above. The substrate for cell adhesion was coated with a
known β1 integrin ligand, human fibronectin.[66],[67] Cell migration was quantified using a
commercial assay to determine net changes in cell coverage over a fixed incubation time (see
Materials & Methods). We used cytoD, which depolymerizes actin,[65] as a negative control,
which was confirmed to decrease cell migration rates as expected. We found that addition of
exogenous Gal-3 caused a moderate increase in cell migration. Interestingly, Gal-3C treatment
caused a significant reduction in cell migration. Addition of LNnT also showed a significant
decrease in cell migration (Table 2, Fig 3). These experiments support that changes observed
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Fig 1. Lateral mobility of integrins is modulated by the presence of saccharides and lectins. The lateral mobility of integrins were
determined using SPT, and the data from Table 1 are shown. Each sample population is shown as a bean plot,[87] with the logarithmic median
of the diffusion coefficients indicated by a solid line for each population.[87] Each population is shown with a density estimate and horizontal
lines indicate individual diffusion coefficient measurements. Gal-3C and Gal-3 treatments are shown for 50 μg mL-1 concentrations. Diffusion
coefficients are given as log(D), where D is in units of x 10−10 [cm2s-1] or x 10−2 [μm2s-1]. Data were compared to a PBS control using a
student’s t-test to determine p values; *, p 0.05; **, p 0.01; ***, p 0.005; ****, p 0.0001.
https://doi.org/10.1371/journal.pone.0184378.g001
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in lateral mobility and clustering of integrin in the presence of Gal-3 versus Gal-3C could man-
ifest functional changes to integrin activity.
Exogenous galectin-3 effects on cell viability
To further understand the differential regulation of Gal-3 and Gal-3C, we investigated the via-
bility of cells after addition of exogenous Gal-3, Gal-3C, and LNnT using identical conditions
to the migration assays. We observed a significant decrease in viability of cells treated with
LNnT and Gal-3C (Table 3, Fig 4). Importantly, addition of Gal-3 did not change the viability
of cells over the course of incubation. The toxicity of LNnT is most likely due to osmotic stress
due to the high concentration of the oligosaccharide (100 mM). Control experiments with sim-
ilar concentrations of sucrose and lactose also showed toxicity in this assay (Table D in S1
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Fig 2. Clustering of integrins is increased on Gal-3 treated cells. Cells were stained using the same anti-
α5-Cy5 conjugate employed for tracking experiments. Ten fields of stained cells were analyzed using ImageJ
to identify clusters and measure their size. Treatment with Gal-3 resulted in an increase in the size of integrin
clusters. See Table B and Figure A in S1 File. Data were compared to a PBS control, or PBS containing BME
(control) using a student’s t-test to determine p values; *, p 0.05; **, p 0.01; ***, p 0.005; ****,
p 0.0001.
https://doi.org/10.1371/journal.pone.0184378.g002
Table 2. Normalized β1 integrin-mediated cell migration.
Condition N migration†
Buffer control 13 100 ± 1
Cyto D 11 27 ± 1****
Gal-3 12 113 ± 5*
Gal-3C 8 74 ± 5****
LNnT 8 72 ± 3****
†Samples were normalized and compared to the indicated control for significance using a Dunnett’s t-test.
Values shown are the mean ± standard error of mean (SEM).
*, p  0.05
****, p  0.0001.
https://doi.org/10.1371/journal.pone.0184378.t002
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File). Both Gal-3C and LNnT decreased cell viability, albeit to different degrees; and this find-
ing suggested that the decreased migration of cells in these two conditions is, in part, due to
reduced cell viability.
Discussion
Using measurements of β1-integrin lateral mobility, we have found that galectins alter the dif-
fusivity of integrin receptors in the membrane. In HeLa cells, the α5β1 integrin showed a
decrease in lateral mobility when exogenous Gal-3C was added. While the truncated Gal-3C
reduced mobility, the full-length Gal-3 protein (with both the CRD and N-terminal domain)
enhanced integrin mobility. Treatment of cells with high affinity oligosaccharides for Gal-3
increased integrin lateral mobility, although this effect may be complicated by toxicity or the
presence of other ligands. Addition of a bacterial neuraminidase enzyme, NanI, resulted in
decreased high-mobility integrins, but no change in the mean diffusion coefficient. Quantifica-
tion of integrin cluster size on cells treated with Gal-3 found increased clustering, while Gal-
3C alone and LNnT had no apparent effects. Thus, one conclusion from this work is that Gal-3
was able to increase integrin clustering through increased diffusivity of the receptor. We
explored the functional consequences of these changes to adhesion using a FN–β1-integrin cell
Fig 3. Migration of cells treated with Gal-3, Gal-3C and LNnT. Cells were treated for 21 h with buffer
control, Cytochalasin D (197 nM), Gal-3 (50 μg mL-1), Gal-3C (50 μg mL-1), and LNnT (100 mM). Migration
was normalized and compared to buffer control; *, p 0.05; **, p 0.01; ***, p 0.005; ****, p 0.0001.
https://doi.org/10.1371/journal.pone.0184378.g003
Table 3. Viability of cells under cell migration conditions.
Condition N viability†
Buffer control 24 100 ± 3
LNnT 24 84 ± 1****
Gal-3C 12 92 ± 1**
Gal-3 24 98 ± 2
†Samples were normalized and compared to the indicated control for significance using a Dunnett’s t-test.
Values shown are the mean ± standard error of mean (SEM).
**, p 0.01
****, p  0.0001.
https://doi.org/10.1371/journal.pone.0184378.t003
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migration assay. We observed that Gal-3 treatment increased β1-integrin mediated cell migra-
tion, while Gal-3C and LNnT inhibited migration. Inhibition of cell migration by Gal-3C may
be the result of blocking native Gal-3 clustering of the adhesion receptor (Fig 5). Treatment
Fig 4. Viability of cells treated with LNnT, Gal-3C, and Gal-3. Cells were treated for 21 h with buffer
control, Gal-3 (50 μg mL-1), Gal-3C (50 μg mL-1), and LNnT (100 mM). Viability of each condition were
measured using MTS assay.[88] Viability for each condition was normalized and compared to buffer control;
*, p 0.05; **, p 0.01; ***, p 0.005; ****, p 0.0001.
https://doi.org/10.1371/journal.pone.0184378.g004
Fig 5. Model of Gal-3 interactions with integrin. (a.) Glycosylated receptors, such as the integrins, will have reduced binding sites for Gal-3 if they are
heavily sialylated. (b.) Removal of sialic acids by neuraminidase enzymes (or decreased SiaT activity) will increase the number of Gal-3 binding sites present,
and should increase oligomerization (only a dimer is shown for clarity). Oligomers likely interact with cytoskeletal regulators, including talin,[89] which lead to
increased mobility through active processes. (c.) Addition of exogenous Gal-3C or a competitive binder (e.g. LNnT) will disrupt the formation of oligomers.
This will occur either by (d.) competition for dimerization sites or (e.) blocking dimer binding sites.
https://doi.org/10.1371/journal.pone.0184378.g005
Galectin-3 effects on beta-1-integrin mobility
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with LNnT, a high affinity ligand for Gal-3, may also reduce integrin mobility through block-
ing of Gal-3–integrin interactions. Alternative mechanisms involving glycolipids may also be
possible.[68] Together, these results provide quantitation of the effect of Gal-3 on integrin lat-
eral mobility and organization in the membrane; and reveal that Gal-3 likely triggers an active
process which results in increasing lateral mobility of integrins.
Earlier work from our group has found that the lateral mobility of the α5β1 integrin was
reduced by the activity of a native neuraminidase, NEU3.[44] This finding was ascribed to
changes in glycolipid composition which resulted in altered cytoskeletal interactions and
endocytosis of the integrin.[68] To see if changes to integrin glycosylation were occurring
here, we confirmed that NanI and NEU3 treatment altered glycosylation of the β1 chain of the
integrin receptor (Figure C in S1 File).[44] NanI treatment resulted in a change to the diffusion
profile of the integrin receptor, but did not cause a significant decrease in average mobility.
We speculate that NanI treatment resulted in the exposure of new cryptic Gal-3 binding sites
on receptors besides the integrin, which could result in sequestration of the native Gal-3 away
from integrin clusters. Our integrin trajectories suggest substantial confinement, consistent
with cytoskeletal interactions. Previous models of Gal-3–integrin interactions have proposed
that clustering of the integrin activates downstream cytoskeletal components (e.g. FAK, Rac-
1),[52] and may involve interactions with glycosphingolipids.[21] Thus, it is likely that the
increased mobility of integrin clusters was due to changes in cytoskeletal processes linked to
endocytosis.[40, 69]
Galectin-3 has previously been found to interact directly with the β1 integrin (CD29).[39,
70] CD7 is also known to be a co-receptor and ligand for Gal-3,[40, 70] but does not appear to
be a ligand for Gal-3 on T cells.[39] Co-localization of the β1 integrin with Gal-3 has been
observed by fluorescence microscopy,[52] but the effect of Gal-3 on the lateral mobility of β1
integrin has not been investigated. Our results indicate that exogenous forms of Gal-3 (both
the holoprotein and the CRD) were capable of altering integrin mobility. The full-length Gal-3
and truncated Gal-3C had opposite effects on lateral mobility and integrin-mediated cell
migration. Gal-3 treatment resulted in increased cell migration, whereas Gal-3C was inhibitory
(Fig 4). These findings are consistent with previous work that found Gal-3 can promote lamel-
lipodia formation[52] and cell migration.[71] Furthermore, Gal-3C is known to inhibit cell
migration and cell growth, and shows mild toxicity above 25 μg mL-1.[72]
Native expression of galectins likely contributes to integrin clustering and mobility. Our
proteomics data confirmed endogenous expression of Gal-1 and Gal-3, suggesting that
untreated cells have a native Gal-3–integrin lattice which may be disrupted through the addi-
tion of ligands such as LNnT. The prevalence of the galectin lattice will be regulated by the
expression of the lectin and the number of binding sites on cellular receptors. The native Gal-3
binding sites should be regulated by the activity of MGAT5,[52, 73] sialyltransferase, and neur-
aminidase enzymes.[8] Treatment of cells with exogenous NanI should have increased the
number of Gal-3 binding sites. Furthermore, native neuraminidase enzymes which directly
modify the integrin, or other adhesion receptors, may influence adhesion through this mecha-
nism.[74, 75]
We used two methods to quantitate changes to the Gal-3–integrin lattice on cells: SPT and
fluorescence microscopy. Single-particle tracking provides a profile of different diffusive
behaviors occurring on the cell surface.[56, 57, 76] For integrin receptors, this can often mani-
fest as a heterogeneous population which may have distinct sub-populations present.[77, 78]
In this study, we found that integrin diffusion could be analyzed as a single log-normal distri-
bution of diffusion coefficients. This finding is consistent with our previous work on β1 integ-
rins, and may be due to the shorter timescale of the measurement used here.[44] Lateral
mobility measurements show significant changes in the presence of Gal-3, likely due to lattice
Galectin-3 effects on beta-1-integrin mobility
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formation and cytoskeletal regulators. Our analysis of Gal-3C treatment by fluorescence
microscopy found no substantial changes to integrin clustering unless cytoD was co-adminis-
tered. Due to the optical resolution of microscopy, these changes in clustering are biased for
large oligomers.
The data presented here provide quantitative support for the formation of a Gal-3–integrin
lattice on the surface of live cells. Our data suggest that disruption of a native galectin–integrin
lattice may occur in the presence of competitive oligosaccharide ligands. The LNnT oligosac-
charide is found in human milk,[79] and these data may lend support to the role of galectins as
HMO receptors.[80] Most importantly, we found that exogenous Gal-3, was able to increase
α5β1 integrin clustering and lateral mobility. The effects of Gal-3 on integrin organization also
induce changes in integrin activity, as detected by cell migration. Exogenous Gal-3 increased
cell migration, while the truncated Gal-3C inhibited cell migration. Our findings suggest that
aggregation and disruption of the galectin–integrin lattice by high affinity ligands or competi-
tive inhibitors could be used to disrupt cell migration. Future work should address the effects
of Gal-3 on additional co-receptors to determine if the lattice manifests target-specific effects
on lateral mobility, and could explore the activity of higher affinity ligands for Gal-3.[81]
Materials & methods
Reagents and cell lines
Phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, Oakville, Ontario, Canada) and Clos-
tridium perfringens neuraminidase (pfNeu, the NanI isoform;[44] Sigma-Aldrich, Oakville,
Ontario, Canada) were dissolved in PBS as stock solutions. Lactose (Gal-β1,4Glc; Sigma-
Aldrigh, Oakville, Ontario, Canada) and lacto-N-neotetraose (LNnT; Gal-β1,4GlcNAc-
β1,3Gal-β1,4-Glc; Elicityl, Grenoble, France) were both used at a final concentration of 100
mM. Cytochalasin D (cytoD; Sigma-Aldrich, Oakville, Ontario, Canada) was dissolved in a
dimethyl sulfoxide (DMSO) stock solution and used after dilution to a final concentration of
500 ng mL-1 with 0.05% DMSO in cell media or buffer.
HeLa cells were a kind gift of Prof. R.E Campbell (University of Alberta). HeLa cells were
cultured and maintained in Dulbecco’s modified Eagles medium (DMEM; Gibco, Invitrogen,
USA) containing penicillin/streptomycin (Gibco, Invitrogen, USA) and 10% fetal bovine
serum (Hyclone, Thermo, USA). Cells were used between 3 and 7 passages, and grown at 37˚C
in a humidified incubator with 5% CO2.
Recombinant human Galectin 3 C-terminal domain (Gal-3C), and Galectin 3 wild type
(Gal-3) were produced as previously described with minor modifications (see S1 File).[63, 82]
Proteomics analysis of Gal expression in HeLa
Carbohydrate modified sepharose gel was prepared as previously reported.[83] One mL of set-
tled Sepharose CL-6B (GE Healthcare Life Sciences, Piscataway, N.J.) was thoroughly washed
with water in a sintered funnel and then re-suspended in 0.5 M carbonate buffer (pH 11) with
100 μL of divinyl sulfone (Sigma Aldrich, Milwaukee, WI). The mixture was agitated for 70
min, after which the resin was transferred to a sintered funnel and extensively washed with
water. The moist cake was suspended in a 1 mL solution of the indicated carbohydrate (1.11
mmol mL-1 in 0.5 M carbonate buffer, pH 10) and left agitating for 18 h. The resin was washed
again with distilled water over a sintered funnel, and the moist cake re-suspended in carbonate
buffer (1 mL, 0.5 M, pH 8.5) with 2-mercaptoethanol (6 μL). After 2 hrs the sample was washed
with distilled water and stored in 20% ethanol solution.
Affinity chromatography was performed by equilibrating the resin with running buffer (20
mL; 0.5 M NaCl, 1 mM CaCl2, 20 mM Tris-HCl, pH 8), followed by injection of the protein
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solution (5 mL). The column was washed with additional running buffer (10 mL), and then
eluted with elution buffer (20 mL; 0.2 M Lac, 3M NaCl, 50 mM Tris-HCl, pH 8) followed by
glycine buffer (20 mL; 0.1 M glycine, pH 2.3). The flow-through from the elution buffer was
collected and concentrated by ultrafiltration.
In-solution digest of the eluent was performed according to reported protocols.[84] Briefly,
the protein solution was precipitated with a chloroform and methanol mixture. The protein
pellet was dried over a stream of nitrogen and then dissolved in 8 M urea, followed by addition
of iodoacetamide (20 mM final concentration) and DTT (10 mM final concentration). The
resulting protein mixture was digested with trypsin and then quenched with formic acid (10%
v/v) and used for analysis by ESI-MS. Data was analyzed with MASCOT.[85]
Cell treatment and single particle tracking
Cell samples were prepared by washing 1 x 105 cells into fresh media after centrifugation at
1200 rpm for 2 min, which were then allowed to settle onto a poly-L-lysine-treated (10 μg mL-1)
confocal dish overnight at 37˚C. Cells were treated by incubation at 37˚C for 0.5 or 2 hours as
indicated. For oligosaccharide incubations, cells were re-suspended in 1 mL of PBS, or oligosac-
charides (100 mM; Lac, 34.23 mg mL-1; LNnT, 70.76 mg mL-1) in PBS. For Gal-3 and Gal-3C
incubations, cells were resuspended in 1 mL of PBS, or Gal-3 (25 μg mL-1 or 50 μg mL-1) in
PBS, or Gal-3C (50 μg mL-1) in PBS. After incubation, all treated cells were washed 3 times with
fresh PBS before labelling and analysis.
Cells were labeled with Cy5-anti-CD49e (clone: SAM-1; 100 ng mL-1) to stain for the α4
integrin complex for 30 minutes at room temperature in the dark. Attempts to label the cells
with the Cy5-F(ab) were unsuccessful, so the intact IgG was used for all experiments. The
Cy5-antibody conjugate was generated using an NHS ester of Cy5 (GE Healthcare, Bucking-
hamshire, UK) following the manufacturer’s protocol. Cells were washed 3 times with PBS
buffer after labelling, and then observed on a Nikon ECLIPSE Ti microscope system by total
internal reflection fluorescence (TIRF) at 37˚C, with a 60x oil objective at 633 nm. Video data
were processed using and NIS-Elements v3.5 (Nikon, USA) for 10 sec and analyzed with u-
track[76] with custom scripts written in MATlab (2012b).[78, 86] Trajectories shorter than 20
steps were excluded. The intensity of the trajectories was used to exclude the top and bottom
5% of trajectories from the analysis.
Immunofluorescence imaging
Immunofluorescence imaging for cluster analysis was performed using an identical protocol
as SPT with 100 ng mL-1 of the antibody conjugate. Random fields were selected to obtain
images of approximately ten cells for analysis. Cells were selected based on DIC and fluores-
cence staining. Images of individual cells were processed in ImageJ by applying a threshold
and processing using the analyze particle function to measure clusters larger than 4 pixel2
(0.7 μm2). Data were analyzed as the average cluster size (μm2 cluster-1) on a per cell basis
(n = 5–15 cells).
Cell migration studies
Migration studies were done using an Oris 96-well plate assay kit (Platypus Technologies, USA)
using the manufacturers protocol. Briefly, the migration surfaces were coated with fibronectin
(10 μg mL-1 in PBS, Calbiochem, USA) for 2 h and 100 μL of IgG-free BSA (200 μg mL-1 in PBS,
Sigma Aldrich, USA) for 1 h. After that, stoppers were placed in each well, and plates were incu-
bated with 50 x 103 cells mL-1 for 18 h. Stoppers were then removed and images of each well
were taken under bright field using a 4x objective with a Nikon T1 Eclipse inverted microscope
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as time zero. The experimental plate was incubated for 21 h to allow cells to migrate. Cells were
treated with buffer alone or with Gal-3 (50 μg mL-1), Gal-3C (50 μg mL-1), and LNnT (100 mM)
in DMEM supplemented with 10% heat inactivated FBS. Images of plate wells were imaged
again and compared with the images at time zero. The difference in area was measured using
Image J software. For each condition the experiment was conducted in at least triplicate mea-
surements performed on separate days to account for intra-day and inter-day variabilities.
Migration area for each replicate was normalized to that of an intra-day buffer control. Normal-
ized replicates were then pooled together for statistical analysis.
Normalization of data was performed by using the following equation: r ¼ A0   A21MB
 
 100.
Where, r is the normalized migration, A0 is the cell-free area at time zero (μm2), A21 is the cell-
free area at 21 h incubation (μm2), and MB is the mean cell-free area in the control after 21 h
(μm2).
Viability studies
Toxicity of compounds was assayed using identical conditions as those in migration studies.
Viability of cells was determined using a CellTiter 96 AQueous Cell Proliferation Assay kit
(MTS) from (Promega, USA) using the manufacturers protocol. Briefly, wells of a 96-well
plate were seeded with 100 μL of 50 x 104 cells mL-1, and incubated for 18 h in a 5% CO2 incu-
bator at 37˚C. Cells were then treated with Gal-3 (50 μg mL-1), Gal-3C (50 μg mL-1), and
LNnT (100 mM) in DMEM supplemented with 10% heat inactivated FBS for 21 h. After incu-
bation for 21 h, 20 μL of an MTS solution was added to each well and incubated for 2 h. The
absorbance of soluble formazan produced by viable cells from MTS was measured at 490 nm
using a SpectraMax M2 (Molecular Devices) plate reader.
For each condition the experiment was conducted in at least triplicate measurements on
multiple days to account for intra-day and inter-day variabilities. Absorbance for each repli-
cate was normalized to that of the intra-day buffer control. All replicates of a condition were
then pooled together for statistical analysis. The data were normalized by dividing the absor-
bance of the sample by the mean absorbance of the buffer control.
Supporting information
S1 File. The file includes proteomics data (Table A), analysis of fluorescence microscopy data
(Table B), lateral mobility controls (Table C), and cytotoxicity controls (Table D), fluorescence
microscopy (Figure A), lateral mobility data with NanI treatment (Figure B), and western blots
of α5β1 integrin after NEU treatment (Figure C).
(PDF)
S2 File. Diffusion data. A table of fit microdiffusion values for the conditions shown in Fig 1.
(XLSX)
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